InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,982.38
(
-0.33%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biotechnewbee

Send PM Follow Ignore
Followers 0
Posts 39
Boards Moderated 0
Alias Born 12/02/2008

biotechnewbee

Re: None

Friday, 04/10/2009 5:17:49 PM

Friday, April 10, 2009 5:17:49 PM

Post# of 19309
Noteworthy items from an analyst report

A Phase 2 trial for the treatment of disseminated intravascular
coagulation (DIC) in severe sepsis is currently on hold while the ATryn program is being transferred to the privately held
LFB Pharmaceuticals.

GTC Biotherapeutics has also commenced the development
of a portfolio of 4-5 follow-on MAbs, which could present attractive partnership opportunity to large pharmaceutical
companies.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up